Relapsed/refractory aggressive large B cell lymphoma (LBCL) remains an area of unmet
need. Here we report the primary analysis of a phase 1b/2 trial of outpatient …

T-cell engaging–therapies have transformed the treatment landscape of relapsed and
refractory B-cell non-Hodgkin lymphomas by offering highly effective treatments for patients …

The approval of CD19-directed chimeric antigen receptor (CAR) T-cell therapies for the
second-line treatment of high-risk large B-cell lymphoma (LBCL) has greatly affected …

Importance The US Food and Drug Administration's (FDA) accelerated approval pathway
allows approval of investigational drugs treating unmet medical needs based on changes to …

Introduction Significant proportion of patients with diffuse large B-cell lymphoma (DLBCL) is
refractory or relapse (R/R) after the treatment. The prognosis of this patient cohort remains …

Overall, around 40% of patients with diffuse large B-cell lymphoma (DLBCL) have refractory
disease or relapse after the first line of treatment. Until relatively recently, the prognosis of …

Purpose: This phase II clinical trial evaluated the combination of ibrutinib with rituximab,
gemcitabine, and oxaliplatin (R-GemOx) in patients with nongerminal center B-cell–like (non …

Purpose: This phase II clinical trial evaluated the combination of ibrutinib with rituximab,
gemcitabine, and oxaliplatin (R-GemOx) in patients with nongerminal center B-cell–like (non …

Antibodies and antibody-based immunotherapeutics are the mainstays of cancer
immunotherapy. Expanding the repertoire of cancer-specific and cancer-associated …

Simple Summary Diffuse large B cell lymphoma is the most common type of B cell
neoplasm, and can be cured by traditional chemoimmunotherapy in 60–70% of cases …